BCL2 and myeloid neoplasm: However, in response to BCL-2 inhibition with venetoclax, myeloid malignancies tend to upregulate and depend on other members of BCL-2 family, such as myeloid cell leukemia-1 (MCL-1), as mechanisms of venetoclax resistance [43, 57].